Zhifei Biologic unit's liraglutide injection begins clinical use in China
Chongqing Chenan Biopharmaceutical, a controlling subsidiary of Zhifei Biologic, has completed the first nationwide injection of its self-developed liraglutide injection, marketed under the brand name Dashuchen, at Banan Hospital of Chongqing Medical University, also known as Chongqing Banan District People's Hospital. The liraglutide injection has formally entered clinical use.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 60/100 and 70% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.